Welcome to our dedicated page for Envveno Medical Corporation news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical Corporation stock.
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device company developing bioprosthetic, tissue-based venous valves for deep venous disease. This news page aggregates company announcements, press releases, and market disclosures related to enVVeno’s clinical programs, regulatory interactions, and corporate actions.
Readers can follow updates on VenoValve®, enVVeno’s first-in-class surgical replacement venous valve for severe deep chronic venous insufficiency and deep venous insufficiency, as well as enVVe®, its non-surgical, transcatheter-based replacement venous valve for deep venous CVI. News items include information on pivotal clinical studies, health economic analyses, and the company’s discussions with the U.S. Food & Drug Administration, such as the not-approvable letter for the VenoValve PMA application and the subsequent supervisory appeal process.
In addition to clinical and regulatory developments, this feed covers financial and corporate news, including quarterly financial updates, capital-raising arrangements like the at-the-market equity program, and shareholder matters disclosed in proxy statements and Form 8-K filings. Announcements about investor presentations, virtual investor segments, and other outreach events featuring enVVeno’s leadership are also reflected here.
For investors and observers tracking NVNO, the news page offers a centralized view of how enVVeno is progressing its venous valve technologies, responding to regulatory feedback, and managing its capital structure through actions such as a board-approved reverse stock split. Regularly reviewing this page can help users understand the evolving context around enVVeno’s development pipeline, regulatory milestones, and key corporate decisions.
enVVeno Medical Corporation (NASDAQ:NVNO) has successfully completed its rebranding and is now trading under the ticker symbol NVNO. Formerly known as Hancock Jaffe Laboratories, the company focuses on innovative bioprosthetic solutions for venous disease treatment. The lead product, VenoValve, aims to address deep venous Chronic Venous Insufficiency (CVI), impacting over 2.4 million people in the U.S. The device is under evaluation in the SAVVE pivotal study, with data anticipated in late 2022.